Additionally, oxaliplatin-induced NOTCH signaling could be interrupted by GSK-J4 treatment in colorectal cancer [74], while there was no evidence showing that both VX-680 and GSK-J4 regulated STAT3 in the progression of tumors. The gene discussed is STAT3; the disease is colorectal cancer.